Table 1.

Summary of recommendations for viral entry targeted antivirals. A list of the antivirals that target viral entry is provided, as well as the recommended time of treatment during disease progression. Note that only one antiviral is recommended as preventative treatment (before infection has occurred); the majority are recommended for mild to moderate infection, none are recommended for severe infection, and two are not currently authorized for COVID‐19 treatment.

Antiviral	Timing of treatment	References
Evusheld	Preventative	[9]
REGEN‐COV	Mild to moderate infection	[10]
BNE	Mild to moderate infection	[11, 12]
Bebtelovimab	Mild to moderate infection	[13]
Sotrovimab	Mild to moderate infection	[14]
Arbidol	Not authorized for COVID‐19 treatment	[15, 16, 17, 18, 19]
Chloroquine	Not authorized for COVID‐19 treatment	[20]